Doxycycline in Type II Diabetes

ConditionDiabetes Mellitus, Type 2

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age40-60

SponsorMostafa Bahaa

About this trial

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5

Disqualifiers

Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Trial design

Design model

Parallel

Treatments tested in this trial

Sitagliptin 100mg
Drug
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
Doxycyclin
Drug
Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.

Treatment groups

60 Participants

are divided into 2 treatment groups

Group A: control groupActive comparator 1 intervention

Group B: Comparative groupActive comparator 2 interventions

Trial outcomes

Primary outcomes

Change in glycemic profile

measurement of fasting blood glucose (FBG)

Time frame

3 months

Change in glycemic profile

measurement of glycated hemoglobin

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mostafa Bahaa

Lead sponsor

Tanta University

Sponsor institution

Source ClinicalTrials.gov

Apply now